“Today marks a large milestone for Bausch + Lomb and an vital phase forward on the route to an independent company concentrated on eye health,” stated Joseph Papa, chairman and CEO, Bausch + Lomb. “Bausch + Lomb has long been connected with quite a few of the most important improvements in eye wellbeing, and I am honored to function alongside our 12,000 world-wide workforce as we carry on to focus on acquiring our ongoing mission of supporting people see superior to dwell improved all about the globe.”
As a thoroughly integrated eye health and fitness enterprise, Bausch + Lomb presents a complete portfolio of a lot more than 400 solutions spanning speak to lenses, lens and eye care products and solutions, ophthalmic prescription drugs, above-the-counter solutions and ophthalmic surgical products and devices. Considering the fact that its founding in 1853, Bausch + Lomb has been committed to advancing eye well being for persons all more than the environment, and has pioneered hundreds of innovations, which includes SofLens, the 1st mass-produced comfortable get in touch with lens. Bausch + Lomb’s existing portfolio involves market-major solutions, this sort of as Biotrue and renu multi-objective methods, Biotrue ONEday daily disposable speak to lenses, LUMIFY redness reliever eye drops, PreserVision AREDS 2 components eye vitamin and mineral dietary supplements and VYZULTA (latanoprostene bunod ophthalmic answer), .024%.
“Over the training course of our company’s practically two century long background, Bausch + Lomb has always stood at the forefront of reducing-edge scientific and technological optical enhancements, and these days is no various. We are a lot more concentrated than at any time on building and featuring new treatment options to meet up with unmet eye health and fitness demands,” ongoing Papa.
Bausch + Lomb now has tasks in several phases of pre-medical and scientific improvement, like new above-the-counter eye care solutions, call lenses, progressive application and prescription medicines for myopia administration, following-generation cataract and LASIK surgical tools, premium intraocular lenses, investigational treatments for dry eye and preservative-cost-free formulations of a range of eye drops.
Potent, Knowledgeable Leaders Picked for Board of Directors and Govt Administration Team
The Bausch + Lomb Board of Directors, which contains the pursuing folks, has a equilibrium of strong small business and health and fitness care knowledge:
- Joseph C. Papa, Chairman
- Thomas W. Ross, Sr., Guide Unbiased Director
- Nathalie Bernier
- Richard U. DeSchutter
- Sarah B. Kavanagh
- John A. Paulson
- Russel C. Robertson
- Andrew C. von Eschenbach, M.D.
The Bausch + Lomb government management workforce includes:
- Joseph C. Papa, Chairman and CEO
- Christina Ackermann, Executive Vice President & Typical Counsel, and President, Ophthalmic Prescription drugs
- Dennis Asharin, Govt Vice President, Main World Producing and Source Chain Officer
- Sam Eldessouky, Main Fiscal Officer
- Joseph (Joe) Gordon, President, Worldwide Purchaser, Surgical and Eyesight Treatment
- Yehia Hashad, M.D., Govt Vice President of Exploration & Growth and Main Medical Officer
- Louis Yu, Ph.D., Government Vice President, Main Top quality Officer
- Kelly Webber, Government Vice President, Chief Human Means Officer
Supply website link